UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000012044
Receipt number R000014078
Scientific Title Prospective Cohort Study on efficacy and safety of transcutaneous minocycline (MINO) injection therapy for patients of simple giant hepatic cysts.
Date of disclosure of the study information 2013/10/16
Last modified on 2018/10/02 14:29:32

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Prospective Cohort Study on efficacy and safety of transcutaneous minocycline (MINO) injection therapy for patients of simple giant hepatic cysts.

Acronym

Prospective Cohort Study on efficacy and safety of transcutaneous minocycline (MINO) injection therapy for patients of simple giant hepatic cysts.

Scientific Title

Prospective Cohort Study on efficacy and safety of transcutaneous minocycline (MINO) injection therapy for patients of simple giant hepatic cysts.

Scientific Title:Acronym

Prospective Cohort Study on efficacy and safety of transcutaneous minocycline (MINO) injection therapy for patients of simple giant hepatic cysts.

Region

Japan


Condition

Condition

Simple giant hepatic cysts

Classification by specialty

Hepato-biliary-pancreatic medicine

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

We will explore efficacy and safety of transcutaneous MINO injection therapy following puncture and drainage for patients of simple giant hepatic cyst.

Basic objectives2

Others

Basic objectives -Others

We will explore efficacy and safety of transcutaneous MINO injection therapy following puncture and drainage for patients of simple giant hepatic cysts.

Trial characteristics_1

Confirmatory

Trial characteristics_2

Pragmatic

Developmental phase



Assessment

Primary outcomes

The primary outcome is to research the recurrence rate of simple giant hepatic cysts. The recurrence case is defined as follows;
-Patients who have abdominal distension
-Patients who have prominent tendency to large in cyst size
-Patients who have liver dysfunction
-Patients who have bleeding and infection in hepatic cysts
-Patients who have risk of hepatic cyst rupture
-Patients who have acute abdomen due to torsion
-Patients who have dilatation of bile ducts
The recurrence rate will be calculated as accumulated recurrence rate for 3 years.

Key secondary outcomes

The secondary outcome is reduction rate of cysts at each evaluation period. The reduction rate will be calculated by cyst volume based on CT results comparing at the time of pre-treatment to post- treatment. We will evaluate the changes in symptoms between pre-treatment and post-treatment.


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine Device,equipment Maneuver

Interventions/Control_1

We will perform puncture, drainage and MINO injection therapy for patients of hepatic cysts.

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

90 years-old >=

Gender

Male and Female

Key inclusion criteria

-Patients who have never received this treatment before
-Patients who satisfy at least one of the following conditions;
a. Patients who have abdominal distension
b. Patients who have prominent tendency to large in cyst size
c. Patients who have liver dysfunction
d. Patients who have bleeding and infection in hepatic cysts
e. Patients who have risk of hepatic cyst rupture
f. Patients who have acute abdomen due to torsion
g. Patients who have dilatation of bile ducts
-Patients who require this treatment instead of the alternative treatment such as surgery
-Patients from whom consent has been obtained to participate in this study, which has been approved by the ethics committee

Key exclusion criteria

a. Patients who have malignant tumors.
b. Patients who have multiple hepatic cysts congenitally such as polycystic kidney disease.
c. Patients whose cysts are connected to vessels and bile ducts
d. Patients who have more serious disease compared to simple giant hepatic cysts.

Target sample size

10


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Yuichi Nozaki

Organization

National Center for Global Health and Medicine

Division name

Department of Gastroenterology

Zip code


Address

1-21-1 Toyama, Shinjuku-ku, Tokyo

TEL

03-3202-7181

Email

ynozaki@hosp.ncgm.go.jp


Public contact

Name of contact person

1st name
Middle name
Last name Yuichi Nozaki

Organization

National Center for Global Health and Medicine

Division name

Department of Gastroenterology

Zip code


Address

1-21-1 Toyama, Shinjuku-ku, Tokyo

TEL

03-3202-7181

Homepage URL


Email

ynozaki@hosp.ncgm.go.jp


Sponsor or person

Institute

National Center for Global Health and Medicine,
Department of Gastroenterology

Institute

Department

Personal name



Funding Source

Organization

National Center for Global Health and Medicine

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor

National Center for Global Health and Medicine, Kohnodai Hospital

Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

国立国際医療研究センター(東京都)


Other administrative information

Date of disclosure of the study information

2013 Year 10 Month 16 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Terminated

Date of protocol fixation

2013 Year 10 Month 16 Day

Date of IRB


Anticipated trial start date

2013 Year 10 Month 16 Day

Last follow-up date

2020 Year 09 Month 30 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2013 Year 10 Month 15 Day

Last modified on

2018 Year 10 Month 02 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000014078


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name